World's First Multiplex Biochip Identifies COVID, Flu, RSV, and Respiratory Pathogens in Less than 60 Seconds

The game-changing technology can accurately identify the specific virus or bacteria in less than a minute, paving the way for an ultra-rapid, portable, and accurate syndromic diagnostic device to provide healthcare providers with immediate results at their fingertips.

The tiny groundbreaking polymer-based biochip developed by Opteev Technologies (Baltimore, MD, USA) is capable of detecting whole viruses in real-time in processed as well as unprocessed samples like saliva or nasal swabs. It has shown an unparalleled accuracy rate of 99.49%, with an impressive detection limit in its performance evaluation. In a complex sample, the biosensor accurately identifies target viruses by using carefully selected virus-binding peptides, enhancing its specificity. The biochip employs artificial intelligence to fine-tune the detection frequency range, effectively reducing the effects of interfering noise signals, and ensuring the reliability and precision of virus detection.

In contrast to conventional respiratory panels that are expensive and require days for delivering results, Opteev's biochip offers a cost-effective solution for syndromic testing. It facilitates point-of-care processing of samples, providing simultaneous detection and specific identification of various pathogens. This game-changing technology eliminates guesswork, equipping healthcare providers with crucial information needed for effective treatment right at the point of care.

"With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies. "The potential of this technology to transform patient care, streamline operations, and reduce costs is truly remarkable."

Related Links:
Opteev Technologies